INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 16, 2021 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 46,925 | $625.25 | 889,785 |
| Aug 16, 2021 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 2,302 | $626.10 | 887,483 |
| May 01, 2024 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Other acquisition or disposition | -- | -- | 886,383 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | $52.03 | 880,938 |
| Dec 14, 2010 |
Director, EVP CSO & Pres Regn Res Labs
|
Director, EVP CSO & Pres Regn Res Labs | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 870,375 |
| Mar 26, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Open market or private sale of non-derivative or derivative security | 32,140 | $120.21 | 867,216 |
| Mar 26, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Open market or private sale of non-derivative or derivative security | 1,010 | $121.09 | 866,206 |
| May 01, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Open market or private sale of non-derivative or derivative security | 100 | $133.95 | 866,106 |
| Dec 14, 2011 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 38,516 | $51.18 | 860,754 |
| May 01, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Open market or private sale of non-derivative or derivative security | 20,120 | $134.54 | 845,986 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.